A venture-backed US biotech company was developing a preclinical biologic for haematological indications and wished to quantify the commercial opportunity for the product in treating myelofibrosis (MF). Alacrita was commissioned to perform an in-depth analysis of the current clinical treatment landscape and market in MF and identify the addressable target opportunity for the product.
Alacrita's approach was to conduct primary and secondary research and to use the insights gained to build a forecasting model for the addressable patient population and potential revenue for the product. Primary research was undertaken in the form of interviews with MF physicians to gain key insights into current treatment practices, unmet needs, and physician interest in a new biologic with a novel MOA. Secondary research strengthened our understanding of any competitive threats in the clinical pipeline. Our final analysis was provided in the form of a slide deck and an Excel sales forecast model, credibly describing the market opportunity for the candidate to be presented to corporate investors and affirm its priority within the pipeline.
The payer environment for innovative therapies is becoming increasingly competitive. Leverage our team’s industry experience in pharmaceutical market access, market research and strategic planning. We will work with you to map a clear path towards optimized access and value-based pricing for your new products. Through specialists in our consulting network, we also provide senior medical affairs expertise, which has helped clients drive alignment at the commercial and medical interface.